Calcipotriene vs Opzelura

When to Apply: A thin layer twice a day, roughly twelve hours apart, on affected skin only. Wash your hands afterwards unless your hands are being treated. Two limits are on the label, not suggestions: no more than 20% of your body surface at a time, and no more than 60 grams a week, or 100 grams over two weeks. One palm is about 1% of your body surface.

How to Start: Twice daily from day one. For eczema, keep going until the skin is clear, then stop — the label calls it short-term, on-and-off treatment. For vitiligo it is the opposite: use it steadily. Stopping early is the usual reason it appears not to work.

If It Irritates: Redness, itch or a mild sting where you apply it is the usual early complaint and it settles. Acne or small bumps at the site is the other common one, most often on the face in vitiligo treatment, and it is treatable rather than a reason to stop. Moisturizing afterwards helps both.

If It's Not Working: For eczema, reassess at 8 weeks; if the skin is not clear, the label says stop and reconsider. For vitiligo, do not judge before 24 weeks. Repigmentation is slow, it starts on the face, and hands and feet may show very little for a long time. No change by about six months is when your doctor will usually add narrowband UVB light treatment.

For most healthy people using it within the label limits, no routine blood tests are needed. Blood levels from the cream are very low, and the trials did not find the blood count or cholesterol changes the tablet causes.

Your doctor monitors the label's safety concerns by asking rather than testing. Expect questions about blood clots, heart attack or stroke, smoking, cancer, tuberculosis exposure, hepatitis, and whether anything else you take suppresses your immune system. This cream is not meant to be combined with other JAK inhibitors, biologics or strong immunosuppressants.

They will check the response on schedule — 8 weeks for eczema, 24 weeks and then longer for vitiligo — and ask about infections, unexplained fever, night sweats, weight loss, chest pain, breathlessness and leg swelling. Some doctors check blood counts and cholesterol at baseline in people with other risk factors.

Skin checks matter for a different reason — unpigmented skin burns easily, so an annual look at the skin is sensible regardless.

First few minutesApplying it: A thin layer twice a day. Mild stinging or redness where you apply it is the usual side effect.

Days 1 to 7Adjusting: For eczema, itch often improves within the first few days, sometimes the first day — among the quickest of any topical. For vitiligo, nothing visible yet.

Weeks 2 to 4Working, eczema: Redness fades and the rash flattens. Most of the eczema improvement happens here.

Weeks 4 to 8Judge it here, eczema: Week 8 is the fair point. If the skin is not clear, the label says stop and reconsider.

Weeks 8 to 24Working, vitiligo: The first sign is small pigmented dots inside a patch, often around hairs, which spread and join up. The face and neck move first, and around a third of people reach 75 percent repigmentation of the face by about six months.

Months 6 to 12 and beyondContinuing, vitiligo: By about a year roughly half reach that 75 percent mark on the face. The trunk and limbs are slower, and skin with hair does better, because surviving pigment cells live in hair follicles. Where vitiligo is still spreading, the cream helps hold the line.

ThroughoutWatch for: Acne or small bumps at the site. Report any fever, unusual infection, chest pain, breathlessness or swollen painful leg.

Cost is the honest sticking point. Ruxolitinib cream is brand only with no generic, and a 60-gram tube lists at a few thousand dollars. Since a tube is one week's maximum, sustained use is expensive at list price.

Almost nobody pays that, but almost everybody has to work for coverage. A prior authorization is standard. For eczema, plans typically want a topical steroid and often a calcineurin inhibitor tried first. For vitiligo, coverage has been harder because some plans treat it as cosmetic — a letter from your dermatologist explaining that vitiligo is an autoimmune disease with real medical and psychological effects is usually what turns that around. Denials are frequently overturned on appeal.

The manufacturer runs a copay program that can cut the cost a lot with commercial insurance, plus patient assistance for people who qualify. Terms change often. People on government insurance are usually not eligible for copay cards, which is a real gap.

One practical point: the drug is priced by the tube, so treating only the areas that need it is a cost decision as well as a safety rule.